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https://doi.org/10.1016/j.celrep.2020.107849SUMMARYReplication-blocking DNA lesions are particularly toxic to proliferating cells because they can lead to
chromosome mis-segregation if not repaired prior to mitosis. In this study, we report that ZGRF1 null cells
accumulate chromosome aberrations following replication perturbation and show sensitivity to two potent
replication-blocking anticancer drugs: mitomycin C and camptothecin. Moreover, ZGRF1 null cells are defec-
tive in catalyzing DNA damage-induced sister chromatid exchange despite accumulating excessive FANCD2,
RAD51, and g-H2AX foci upon induction of interstrand DNA crosslinks. Consistent with a direct role in promot-
ing recombinational DNA repair, we show that ZGRF1 is a 50-to-30 helicase that catalyzes D-loop dissociation
and Holliday junction branch migration. Moreover, ZGRF1 physically interacts with RAD51 and stimulates
strand exchange catalyzed by RAD51-RAD54. On the basis of these data, we propose that ZGRF1 promotes
repair of replication-blocking DNA lesions through stimulation of homologous recombination.INTRODUCTION
Helicases play important roles in DNA replication, transcription,
and repair because of their ability to remodel nucleic acid struc-
tures. Helicases use the energy fromATP hydrolysis to translocate
along DNA or RNA in the 30-to-50 or 50-to-30 direction, which can
lead to strand separation in duplex DNA or in RNA:DNA hybrids.
This activity can alsomelt secondary structures in single-stranded
DNA (ssDNA) or RNAmolecules. The human genome is predicted
to encode more than 95 helicases, some of which are associated
with human diseases (Uchiumi et al., 2015; Umate et al., 2011).
DNA interstrand crosslinks (ICLs) represent one of the most
genotoxic DNA lesions, because they block DNA replication
and, as a consequence, prevent chromosome segregation in
mitosis (Chan et al., 2018). ICLs arise spontaneously at a low fre-
quency in human cells because of aldehydes, nitrous acid, and
other reactive chemicals produced by normal cellular meta-
bolism (reviewed in Lopez-Martinez et al., 2016). Notably, rapidly
dividing cancer cells are hypersensitive to ICL-inducing drugs
such as mitomycin C (MMC), cisplatin, and oxaliplatin, which
are used as cancer therapeutic agents. ICLs are repaired by
the Fanconi anemia (FA) pathway during S phase when an X-
shaped DNA structure is generated around the lesion via replica-
tion fork convergence or single-fork traverse of the ICL (Huang
et al., 2013; Zhang et al., 2015). ICL repair via the FA pathway
is initiated upon lesion recognition of the ICL by the UHRF1This is an open access article under the CC BY-Nand UHRF2 proteins (Motnenko et al., 2018) and the FANCM-
MHF1-MHF2-FAAP24 complex, which recruit the FANCI-
FANCD2 (FANCI-D2) heterodimer and the FA core complex to
chromatin, respectively. The FA core complex is an E3 ubiquitin
ligase that monoubiquitylates FANCI-D2 to facilitate recruitment
of SLX4/FANCP and subsequently the association of DNA endo-
nucleases MUS81, SLX1, FAN1, and XPF/ERCC4/FANCQ. At
the X-shaped DNA structures, these endonucleases cleave
one of the parental DNA strands on each side of the ICL, gener-
ating a DNA break across from the ‘‘unhooked’’ ICL adduct on
the other parental strand. Replication of the ICL-containing
strand is completed by translesion synthesis (TLS), and this
strand then serves as a template for repair of the DNA double-
strand break (DSB) remaining on the other strand by
homologous recombination (HR). Finally, the ICL is removed by
nucleotide excision repair to restore DNA integrity (reviewed in
Ceccaldi et al., 2016).
The HR step of ICL repair is catalyzed by the RAD51 recombi-
nase, which is loaded by BRCA2/FANCD1 onto 30 single-
stranded overhangs generated as a result of DSB end resection
(Symington, 2016). RAD51 catalyzes invasion of the 30 single-
stranded end into the sister duplex, where it primes DNA synthe-
sis, leading to an extended D-loop. The D-loop can be resolved
by synthesis-dependent strand annealing (SDSA), which leads
exclusively to non-crossover (NCO) recombination products, or
by classical DSB repair (DSBR), which leads to the formationCell Reports 32, 107849, July 7, 2020 ª 2020 The Author(s). 1
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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OPEN ACCESSof a double-Holliday junction (dHJ) that can be resolved into
either NCO or crossover (CO) recombination products (reviewed
in Zhao et al., 2019). The FANCM translocase promotes SDSA by
disassembling D-loops before they are converted into dHJs
(Deans and West, 2009; Gari et al., 2008). SDSA is thought to
be the preferred pathway for replication-coupled DSBR in mitot-
ically growing cells (Larocque and Jasin, 2010; Zapotoczny and
Sekelsky, 2017), because this will prevent loss of heterozygosity
arising when CO recombination occurs between homologous
chromosomes.
The FANCM-MHF1-MHF2 complex is evolutionarily conserved
in eukaryotes, with Mph1 being the homolog of FANCM in the
budding yeast Saccharomyces cerevisiae. A fourth subunit of
the yeast complex, Mte1 (Mph1-associated telomere mainte-
nance protein 1), was recently identified as a regulator of Mph1
activity (Silva et al., 2016; Xue et al., 2016; Yimit et al., 2016).
Mte1 binds with high affinity to branched DNA molecules such
as D-loops, Y-structures, and Holliday junctions (HJs). Mte1 inter-
acts with Mph1 via its C terminus and selectively regulates the
different activities of Mph1. Mte1 stimulates the replication fork
regression and branch migration activities of Mph1, but D-loop
dissociation by Mph1 is inhibited. In vivo, Mte1 promotes mitotic
CO recombination and protects cells against genotoxic agents
that cause replication stress. TheMte1-Mph1 complex also co-lo-
calizeswithRad52 recombination foci (Silva et al., 2016; Xue et al.,
2016). Similarly, Dbl2/Mte1 in the fission yeast Schizosaccharo-
myces pombe co-localizes with Rad22/Rad52 and Fml1/Mph1,
and dbl2D mutant cells are sensitive to replication stress (Yu
et al., 2013). Human ZGRF1 (zinc finger GRF-type containing 1,
C4orf21) shares homology with Mte1/Dbl2 in its N-terminal
DUF2439 domain. The C terminus of ZGRF1 is not conserved in
Mte1/Dbl2 and is predicted to encode a (GRF-type) Zn finger
DNA binding domain and a helicase domain (Figure 1A). Human
ZGRF1 is largely uncharacterized, but genome-wide small inter-
fering RNA (siRNA) knockdown screens have suggested a role
for ZGRF1 as a regulator of HR and ICL repair (Adamson et al.,
2012; Smogorzewska et al., 2010).
To investigate the roles of ZGRF1 in human cells, we examined
the consequences of genetic deletion of ZGRF1, and we charac-
terized the purified recombinant protein biochemically. We
demonstrate that human ZGRF1-knockout cells are sensitive to
the DNA interstrand crosslinking agent MMC and the topoisomer-
ase I (TOP1) inhibitor camptothecin (CPT). Furthermore, ZGRF1-
deficient cells exhibit elevated levels of chromosome aberrations
after MMC treatment, reduced sister-chromatid exchange (SCE)
followingMMCorCPT exposure, and a defect in gene conversion.
Furthermore, we show that the ZGRF1 protein is a 50-to-30 heli-
case with the ability to remodel DNA molecules, interact with
RAD51, and stimulate RAD51-RAD54-catalyzed DNA strand ex-
change. We conclude that ZGRF1 is a helicase that facilitates
repair of severe replication-blocking lesions by HR.
RESULTS
ZGRF1/ Cells Are Sensitive to DNA Interstrand
Crosslinks and Covalent Protein-DNA Complexes
To investigate the roleofZGRF1 inDNArepair,wecreatedahomo-
zygous knockout of ZGRF1 in the colon cancer cell line HCT1162 Cell Reports 32, 107849, July 7, 2020using CRISPR-Cas9 (Figure S1). Immunoblotting confirmed that
no full-length ZGRF1 protein is produced in the knockout cell lines
(Figure1B). ZGRF1/ cells showaslightly slowergrowth rate than
parental cells (Figure 1C) and increased accumulation in G2/M,
which is similar to what is seen in FANCM/ cells (Figures 1D
and 1E). By contrast, G2-M checkpoint defective FANCJ/ cells
fail to arrest in G2/M upon MMC treatment (Figures 1D and 1E)
(Yu et al., 2003). We examined the sensitivity of ZGRF1/ cells
to a range of DNA-damaging agents using a clonogenic survival
assay. Consistent with results from a previous RNAi screen (Smo-
gorzewska et al., 2010), ZGRF1/ cells exhibited sensitivity to the
DNA crosslinking agentMMC (Figure 1F). ZGRF1/ cells also ex-
hibited mild sensitivity to the TOP1 inhibitor CPT (Figure 1G), but
not to ionizing radiation (Figure 1H), ultraviolet radiation (Figure 1I),
the poly (ADP-ribose) polymerase (PARP) inhibitor talazoparib
(Figure 1J), or hydroxyurea (HU; Figure S4D). These data suggest
that ZGRF1 is critical for cellular responses to DNA replication-
blocking lesions and most notably to ICLs. To confirm that the
MMC sensitivity of ZGRF1/ cells is due to ablation of ZGRF1,
we reverted the mutant alleles back to wild-type (WT) using
CRISPR-Cas9 and confirmed that this fully rescued the MMC
sensitivity of the mutant cell line (Figure 1F).
To analyze whether the DNA damage sensitivity of ZGRF1/
cells extends beyond the HCT116 cell line, we used CRISPR-
Cas9 to target the ZGRF1 gene in the human osteosarcoma
U2OS cell line. Exposure of U2OS parental and ZGRF1/ cells
to increasing concentrations of MMC revealed a sensitivity of the
mutant cell line comparable with that of the ZGRF1/ HCT116
cell line (Figure 1K). Similarly, we showed that knockout of
ZGRF1 in the untransformed primary epithelial cell line RPE-1
causes MMC sensitivity (Figure 1K). These results indicate that
MMCsensitivity is ageneral phenotypeassociatedwithZGRF1/
cells and is not linked to a specific state of transformation.
To further characterize the consequences of MMC exposure at
the chromosomal level, we examined metaphase spreads for
chromosomal aberrations. Treatment of parental cells with
20 ng/mL MMC for 24 h resulted in a small increase in chromo-
somal aberrations (0.56 versus 0.12 aberrations per metaphase
spread in untreated cells). The types of chromosomal aberrations
observed in parental cells were usually confined to small gaps or
breaksonchromosomearms (Figures 2A and 2B). ZGRF1/ cells
exhibited very few chromosomal aberrations when untreated,
which was comparable with parental cells (0.13 and 0.12 aberra-
tions per metaphase spread, respectively). However, they ex-
hibited a significantly higher proportion of metaphase spreads
with aberrations when treated with MMC (1.16 aberrations per
metaphase spread in ZGRF1/ cells versus 0.56 aberrations
per metaphase spread in parental cells; Figures 2A–2C). More-
over, the types of aberrations were altered, with ZGRF1/ cells
harboring larger gaps on chromosome arms, chromosome arm
fusions, and, in rare cases, radial chromosomes (Figure 2C).
Taken together, these data indicate a role for ZGRF1 in the repair
of replication-blocking DNA damage such as those caused by
ICLs and covalent protein-DNA complexes.
ZGRF1 Contributes to the FA Pathway for Surviving ICLs
An important pathway for ICL repair in S phase is the FA
pathway. To examine the relationship between ZGRF1 and the
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Figure 1. ZGRF1 Is Important for DNA Interstrand Crosslink Repair
(A) Domain organization of ZGRF1. The DUF2439 domain is conserved between S. cerevisiae Mte1, S. pombe Dbl2, and human ZGRF1. The DNA binding and
Mph1 interaction domains are indicated for Mte1. The putative DNA binding Zn finger and helicase domains are indicated for ZGRF1.
(B) Western blot of ZGRF1 in HCT116 parental and ZGRF1/ cell lines.
(C) ZGRF1/ cells exhibit slow growth. HCT116 parental and ZGRF1/ cells were cultured for 48 h, and cell density was determined at 24 h intervals. Error bars
indicate SD (n = 5).
(D) ZGRF1/ cells accumulate in G2. Quantification of G2 accumulation in HCT116 parental, ZGRF1/, FANCM /, and FANCJ/ cells in unperturbed
condition and in response to MMC treatment. Means from three independent experiments are plotted as bars. Error bars represent 95% confidence intervals. p
values were calculated using two-way ANOVA on the basis of three independent biological replicates.
(E) Representative cell cycle profiles of propidium iodide stained cells, either untreated or treated with 40 ng/mL MMC for 2 h followed by recovery for 24 h.
(F) Colony formation assay of HCT116 parental, ZGRF1rev/rev, and three independent ZGRF1/ cell lines treated with the indicated doses of MMC for 24 h. The
graph of the parental cell line is statistically different from each of the knockout cell lines (p < 0.05, t test) but not significantly different from ZGRF1rev/rev (n.s.).
(G–J) Colony formation assays of cells treated with the indicated doses of CPT (G) for 24 h, ionizing radiation (X-rays) (H), ultraviolet radiation (UV-C) (I), or the poly
(ADP-ribose) polymerase (PARP) inhibitor talazoparib (J).
(K) Colony formation assay of U2OS and RPE-1 parental and ZGRF1/ cell lines treated with the indicated doses of MMC for 24 h.
nR 3 for each cell line. All graphs show the mean with 95% confidence interval. Statistical significance was calculated using unpaired t tests without assuming
consistent SD. *p < 0.05. n.s., no significant difference.
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OPEN ACCESSFA pathway, we performed immunofluorescence imaging of g-
H2AX, a marker of both stalled and collapsed replication forks
(Sirbu et al., 2011; Ward and Chen, 2001), and FANCD2, a key
FA protein that is monoubiquitylated in response to ICLs and
forms nuclear foci at sites of DNA damage (Garcia-Higuera
et al., 2001; Knipscheer et al., 2009). Therefore, co-localizing
g-H2AX and FANCD2 foci likely mark sites of active repair by
the FA pathway. Interestingly, even under unperturbed condi-
tions, ZGRF1/ cells exhibited increased levels of co-localizing
foci compared with parental cells (Figures 2D and 2E). Following
treatment with MMC, these co-localizing foci accumulated to a
higher level in ZGRF1/ cells (Figures 2D and 2E). Taken
together, these data indicate that ZGRF1/ cells accumulate
DNA lesions that are recognized by the FA pathway. Moreover,
it suggests that ZGRF1 is not required for the activation of the
FA pathway and likely acts downstream of FANCI-D2 monoubi-
quitylation (Garcia-Higuera et al., 2001).
To substantiate this conclusion, we performed epistasis anal-
ysis of ZGRF1 with FANCM and FANCJ. Two independent dou-
ble-mutant cell lines were constructed for each pair of genes by
CRISPR-Cas9 and confirmed by sequencing andwestern blotting
(Figures S2 and S3). The ZGRF1 and FANCM single and double
mutants were significantly more sensitive to MMC than the
parental HCT116 cell line, but not significantly different from
each other, suggesting that ZGRF1/ and FANCM/ are
epistatic for MMC sensitivity (Figure 2F). We were unable to
generate null alleles of FANCJ on both chromosomes in the
ZGRF1/ background, while we could successfully generate
FANCJ null alleles in the parental background. Editing of the sec-
ond FANCJ allele in the ZGRF1/ background repeatedly re-
sulted in in-frame insertions and deletions, suggesting that
ZGRF1/ is synthetic lethal with FANCJ/. Nevertheless, clono-
genic survival of ZGRF1/ cells possibly containing hypomorphic
mutant alleles of FANCJ showed that ZGRF1/ cells containing
FANCJ indels are significantly more sensitive to MMC than
ZGRF1/ alone, and the double mutants exhibit MMC sensitivity
comparable with the FANCJ/ single mutant (Figure 2G). Taken
together, this analysis suggests that ZGRF1 acts in the same
pathway as FANCM. Furthermore, it is likely that FANCJ is criticalFigure 2. ZGRF1 Contributes to the FA Pathway
(A) Quantification of chromosomal aberrations in HCT116 parental and ZGRF1
calculated using Mann-Whitney U tests. NR 32 spreads per condition.
(B and C) Examples of metaphase spreads from parental cells (B) or ZGRF1/ c
chromosomal aberrations. The images shown highlight the types of aberrations
spread.
(D) ZGRF1/ cells show a higher frequency of co-localizing g-H2AX and FAN
Quantification of co-localizing g-H2AX and FANCD2 foci under unperturbed con
95% confidence intervals. p values were calculated using Mann-Whitney U tests
(E) Representative images of HCT116 parental and ZGRF/ cells under unpertur
localizing foci for one cell, where the pixel intensity of FANCD2 foci was a minimum
g-H2AX foci were not scored, as this indicated inadequate immunostaining.
(F) Colony formation assay of HCT116 parental and ZGRF1/ and FANCM/ sing
h. The graph of the parental cell line is statistically different from each of the knoc
different from each other (n.s.).
(G) Colony formation assay of HCT116 parental and ZGRF1/ and FANCJ single-
The graph of the parental cell line is statistically different from the ZGRF1-knocko
not significantly different from each other (n.s.).
Graphs in (F) and (G) show themean with 95% confidence interval. Statistical sign
*p < 0.05. n.s., no significant difference. nR 3 for each cell line.for survival in the absence of ZGRF1, suggesting some functional
redundancy between these two proteins.
MMC Induces Nuclear FANCD2-Co-localizing ZGRF1
Foci during S Phase
To examine the localization of ZGRF1 during ICL repair, we
tagged endogenous ZGRF1 with a tandem Venus-eYFP tag
(2xYFP) at its C terminus. Expression of full-length ZGRF1-
2xYFP was confirmed by western blotting (Figure S4A). Live-
cell microscopy showed that ZGRF1-2xYFP localizes to the
nucleus but with a large cell-to-cell variation in the expression
level (Figure S4B). In contrast, cells synchronized at the G1-S
transition with thymidine displayed a more uniform and higher
level of ZGRF1 (Figure S4C), suggesting that ZGRF1 abundance
is cell cycle regulated and peaks in S phase. To examine the
localization of ZGRF1 during ICL repair, cells were arrested at
the G1-S transition with thymidine and treated with MMC for
4 h before being released into S phase in fresh medium contain-
ing Hoechst for nuclear staining. Fluorescence microscopy of
cells before and after release into S phase showed that MMC
treatment induces the formation of nuclear ZGRF1 foci in S
phase (Figures 3A and 3B). To test if ZGRF1 foci colocalize
with components of the FA pathway, we introduced mCherry-
FANCD2 into the ZGRF1-2xYFP cell line by random integration
(Motnenko et al., 2018) and selected clones that express
mCherry-FANCD2 at levels similar to or slightly lower than
endogenous FANCD2 to avoid any toxic effects that overexpres-
sion may cause (Figure S4E). Live-cell imaging of this cell line
showed that the majority (78%–82%, 992 of 1,216 foci and
1523 of 1,948 foci, respectively) of both spontaneous and
MMC-induced ZGRF1 foci colocalize with FANCD2 (Figures
3C and 3D). Taken together, these data suggest a direct role
for ZGRF1 in the response of the FA pathway to collisions be-
tween replication forks and ICLs during S phase.
ZGRF1 Is Required for HR Repair at Replication-
Blocking Lesions
Several lines of evidence suggest a role for ZGRF1 in promoting
HR. In addition to the observed CPT sensitivity (Figure 1G),/ cells. Means with 95% confidence intervals are plotted. p values were
ells (C) untreated or treated with 20 ng/mL MMC for 24 h. White arrows mark
scored rather than being representative of the number of aberrations seen per
CD2 foci under both unperturbed conditions and when treated with MMC.
ditions and with two different treatments with MMC is shown. Error bars show
. N > 100 cells for each condition.
bed conditions or after treatment with 20 ng/mL MMC for 4 h. Arrows mark co-
of 6,000 arbitrary units higher than background. Cells with very low or absent
le- and double-mutant cell lines treatedwith the indicated doses ofMMC for 24
kout cell lines (p < 0.05, t test), but the knockout cell lines are not significantly
and double-mutant cell lines treated with the indicated doses of MMC for 24 h.
ut cell line (p < 0.05, t test). The FANCJ single- and double-mutant cell lines are
ificance was calculated using unpaired t tests without assuming consistent SD.
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Figure 3. ZGRF1 Colocalizes with FANCD2 at DNA Damage-Induced Foci
(A) ZGRF1 localizes to nuclear foci during ICL repair. Cells expressing ZGRF1-2xYFP from the endogenous promoter were synchronized at the G1/S border by
treatment with 2 mM thymidine for 18 h before release into S phase in Leibovitz’s L-15 medium containing 0.4 mM Hoechst 33258. Four hours before release,
20 ng/mL of MMC or vehicle was added to the cultures. Arrows indicate ZGRF1 foci.
(B) Quantification of ZGRF1 foci after MMC treatment. Quantification of the experiment in (A). Error bars show 95%confidence intervals. p values were calculated
using Mann-Whitney U tests. N = 90–160 cells for each condition.
(C) Colocalization of ZGRF1 and FANCD2. Cells expressing ZGRF1-2xYFP from the endogenous promoter and ectopically integrated mCherry-FANCD2 were
synchronized in S phasewith 2mM thymidine 18 h prior tomicroscopy. Four hours beforemicroscopy, 20 ng/mLMMCor vehiclewas added to the culture. Yellow
arrows mark ZGRF1 foci, red arrows mark FANCD2 foci, and orange arrows mark the co-localizing foci.
(D) Quantification of co-localizing FANCD2 and ZGRF1 foci in the experiment reported in (C).
Error bars show 95% confidence intervals. p values were calculated using Mann-Whitney U tests. N > 400 cells for each condition.
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Figure 4. ZGRF1 Contributes to Homologous Recombination
(A) Schematic illustration of the DR-GFP assay. A recognition site of the I-SceI meganuclease has been integrated into the open reading frame (ORF) of the GFP
gene (SceGFP), thereby disrupting the ORF, and a truncated GFP gene (iGFP) fragment with the correct ORF sequence is placed downstream in the construct.
Repair of the cleaved I-SceI site by gene conversion using the downstream iGFP as a template results in a functional GFP gene that is measured using flow
cytometry. White box, promoter; gray arrow, transcription start site.
(B) ZGRF1 promotes gene conversion. The percentage of GFP-positive cells with (+) or without () I-SceI expression is shown for U2OS DR-GFP parental and
ZGRF1/ cells (p < 0.05, multiple t test). Error bars indicate SEM (n = 4).
(C) Representative images of sister chromatid exchange events (SCEs) in metaphase spreads in cells treated with 0.1 nMCPT for 42 h. Blue and red arrowsmark
non-centromeric exchanges for HCT116 parental and ZGRF1/ cells, respectively, while white arrows mark centromeric exchanges.
(D and E) ZGRF1/ cells show a decrease in the number of non-centromeric SCEs per chromosome compared with HCT116 parental cells. Quantifications of
SCE frequencies in HCT116 parental and ZGRF1/ cells treated with 0.1 nM CPT for 42 h or 20 ng/mL MMC for 24 h are shown. Two independent experiments
were performed. NR 35 metaphase spreads and 674 chromosomes per condition.
Error bars show 95% confidence intervals. p values were calculated using Mann-Whitney U tests.
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OPEN ACCESSknockdown of ZGRF1 was shown in a genome-wide screen to
cause reduced recombination in a green fluorescent protein
(GFP) reporter assay (Adamson et al., 2012). In S. cerevisiae,
deletion of the ZGRF1-related gene MTE1 causes a reduction
in the rate of CO versus NCOproducts resulting from recombina-
tional repair of a DSB (Silva et al., 2016). To examine if ZGRF1
regulates HR, we first validated the impact of ZGRF1 on HR in
the DR-GFP recombination assay (Figure 4A), where a site-spe-
cific DSB induced by the I-SceI meganuclease is repaired by
gene conversion to produce a functional GFP gene (Pierce
et al., 2001), which is scored by flow cytometry. After knockout
of ZGRF1 by CRISPR-Cas9 (Figures S4F and S4G), we observeda 7-fold reduction in the I-SceI-induced DR-GFP recombination
frequency relative to the parental control (Figure 4B).
To test if loss of ZGRF1 also affects recombination induced by
replication-blocking lesions, we measured the frequency of
SCEs, which represent CO events during HR. For this, we
analyzed parental and ZGRF1/ cells mock-treated or treated
with either MMC or CPT, which leads to SCEs that can be visu-
alized in metaphase spreads (Simpson and Sale, 2006). SCEs
that occurred across the centromere (centromeric) or across
the chromosome arm (non-centromeric) were scored separately
(Figures 4C–4E), because a centromeric SCE is indistinguishable
from a twisting of the chromosome arms during chromosomeCell Reports 32, 107849, July 7, 2020 7
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Figure 5. Human ZGRF1 Is a 50-to-30 Helicase that Directly Stimulates RAD51-Catalyzed Strand Exchange
(A) SDS-PAGE analysis of purified ZGRF1 and its helicase dead mutant ZGRF1-K1660A.
(B) ATP hydrolysis by ZGRF1 (wild-type or K1660A mutant) with fX174 viral (+) strand, linear dsDNA (LDS), or replicative form I DNA (RF1).
(C and D) ZGRF1 or ZGRF1-K1660Awas incubatedwith DNA substrates harboring either a 50 (C) or a 30 (D) ssDNA overhang and either ATP or ATP-g-S at 30C for
5 min in the presence of trap oligos to prevent the spontaneous re-annealing of the separated strands. HD, heat denatured.
(E) ZGRF1 interacts with human but not yeast RAD51. GST-ZGRF1 or GST (0.3 mg) was incubated with human or yeast RAD51 (0.5 mg) on Glutathione Sepharose
4B resin. The supernatant (S), wash (W), and SDS eluate (E) were resolved using SDS-PAGE followed bywestern blotting. GST-ZGRF1 or GSTwas detected using
a-GST-HRP antibody, while human or yeast RAD51 was detected using a-hRAD51 or a-yRad51 antibodies.
(F) ZGRF1 and RAD51 interact in vivo. The proximity ligation assay (PLA) was used to examine the interaction between ZGRF1 and RAD51 in HCT116 cells.
Primary antibodies were directed against GFP (to detect ZGRF1-2xYFP) and RAD51, and protein interactions were visualized as fluorescent foci inside the
(legend continued on next page)
8 Cell Reports 32, 107849, July 7, 2020
Article
ll
OPEN ACCESS
Article
ll
OPEN ACCESSspreading. Although there was no significant difference between
ZGRF1/ and parental cells in the levels of centromeric SCEs,
we did observe a significantly lower level of non-centromeric
SCE events in ZGRF1/ cells following treatment with either
MMC or CPT (Figures 4C–4E). These data suggest that ZGRF1
is required to promote HR repair following DNA replication-
blocking lesions.ZGRF1 Exhibits 50-to-30 Helicase Activity
To link the phenotypic characterization of ZGRF1/ cells to the
function of theZGRF1protein,weexpressedZGRF1 in insect cells
and purified the protein to near homogeneity along with a ZGRF1-
K1660A variant in which theWalker Amotif is mutated (Figure 5A).
We observed that WT ZGRF1, but not ZGRF1-K1660A, exhibited
DNA-dependent ATPase activity upon the addition of single- or
double-stranded DNA (dsDNA), or replicative form I DNA (RF1)
(Figure 5B). To test if ZGRF1 possesses helicase activity, we incu-
bated ZGRF1 with helicase substrates that harbor a 15 bp duplex
region and a 45 nt 50 or 30 single-stranded overhang (Figures 5C
and 5D). ZGRF1, but not ZGRF1-K1660A, efficiently dissociated
the substrate with the 50 single-stranded overhang (Figure 5C)
but showed no activity on the substrate with the 30 overhang (Fig-
ure5D). This indicates thatZGRF1 isanATPhydrolysis-dependent
helicase with a 50-to-30 polarity of translocation on ssDNA.ZGRF1 Stimulates RAD51-RAD54 Catalyzed Strand
Exchange
To investigate how ZGRF1 collaborates with other genomemain-
tenance proteins during ICL repair, we first tested the physical
interactionofZGRF1withanumberofcandidateproteinsbyco-af-
finity precipitation. Thismini-screen revealed putative interactions
withFANCM,RAD51, andPold (Figures 5E,S5A, andS5B), but not
with Polε, PCNA, RPA, or yeast Rad51 (Figures S5C and 5E).
Because of the potential role of ZGRF1 inHR,wedecided to focus
on the RAD51 interaction. To analyze whether ZGRF1 and RAD51
interact in situ, we turned toproximity ligation in theZGRF1-2xYFP
cell lineusingantibodiesagainst YFPandRAD51 (So¨derberg etal.,
2006). Using this assay, we observed increased proximity ligation
specifically in the nucleus of oligo-conjugated antibodies directed
toZGRF1-2xYFPandRAD51afterMMCtreatment (Figures5Fand
5G). The MMC-induced increase was not observed in the cyto-
plasm or in the parental cell line or if either of the anti-YFP or
anti-RAD51 antibodies were omitted. We therefore conclude that
RAD51 and ZGRF1 physically interact in the context of ICL repair.
HR is critically dependent on RAD51 to catalyze strand ex-
change between the recombining DNA molecules. To test if the
ability of ZGRF1 to promote recombination in vivo (Figures 4A–nucleus marked by DAPI staining. HCT116 parental cells that do not contain ZGR
controls, where either of the primary antibodies was omitted.
(G) Quantification of PLA in (F). Graph shows quantification of nuclear and cytopla
Mann-Whitney U tests. Error bars represent mean with 95% confidence intervals
(H) Experimental setup for examining RAD51-catalyzed strand exchange. Asteris
(I) ZGRF1 stimulates RAD51-RAD54-mediated strand exchange. Time course an
presence of ZGRF1 or its helicase deadmutant ZGRF1-K1660A was shown. NP, n
(J) ZGRF1 acts downstreamof RAD51 focus formation. HCT116 parental or ZGRF
medium for the indicated amount of time before fixation and immunostaining for
Graphs show the mean with 95% confidence intervals (*p < 0.05, multiple t test)4E) reflects a direct stimulation of RAD51, we examined RAD51-
catalyzed strand exchange in vitro by measuring the invasion of
a 90-mer single-stranded oligonucleotide into a homologous dou-
ble-stranded target to form a D-loop structure in the presence of
the RAD54 translocase (Figure 5H) (Mazina and Mazin, 2004).
ZGRF1 was introduced into the reaction only after RAD51-ssDNA
nucleoprotein filament formation, and just before the addition of
dsDNA to initiate the D-loop formation (Figure 5H). We observed
a 4-fold stimulation of RAD51-RAD54-catalyzed strand exchange
by WT ZGRF1, but not by the ATPase dead ZGRF1-K1660A
mutant (Figure 5I). In comparison, ZGRF1 did not stimulate strand
exchange catalyzed by yeast Rad51-Rad54 (Figures S5D and
S5E), suggesting that the stimulation depends on the direct phys-
ical interaction with human RAD51. Taken together, these ana-
lyses suggest that ZGRF1 promotes recombination by directly
stimulating RAD51 strand exchange activity.
TodistinguishwhetherZGRF1promotes recombinationby facil-
itating the loadingofRAD51at ICLsorprimarily throughstimulation
of RAD51 after its binding to ssDNA, we quantified RAD51 foci in
HCT116 parental and ZGRF1/ cells after a challenge with
1 mg/mL MMC for 1 h. This treatment led to a dramatic increase
in RAD51 foci in both cell lines (Figure 5J), but the ZGRF1/ cells
accumulated RAD51 foci to higher levels, suggesting that ZGRF1
is not required to loadRAD51 at sites of DNA damage, but rather it
promotes recombinational repair after RAD51 recruitment.ZGRF1 Catalyzes Branch Migration and D-Loop
Dissociation
The purified yeastMte1-Mph1-MHF complex can remodel a num-
ber of DNA substrates representing DNA repair and replication in-
termediates (Mitchel et al., 2013; Prakash et al., 2005, 2009; Silva
et al., 2016; Xue et al., 2014, 2016; Zheng et al., 2011). To test if
ZGRF1 has similar activities, we first examined DNA branch
migration using a mobile HJ (MHJ; Figure 6A). Conversion of
this substrate into duplex DNA indicates that ZGRF1 can catalyze
HJ branch migration in a manner dependent on ATP hydrolysis.
Next, we examinedD-loops, which are also important interme-
diates of HR. To test if ZGRF1 can dissociate D-loops, we
assembled 30 bp D-loops with protruding 30 nt 30 or 50 over-
hangs. Incubation of ZGRF1 with any of these substrates led to
the release of the free radiolabeled oligonucleotide in a manner
dependent on ATP hydrolysis (Figures 6B and 6C), indicating
that ZGRF1 can dissociate D-loops irrespective of the orienta-
tion of their overhangs. We also tested a more physiological D-
loop substrate generated by Rad51-catalyzed strand invasion
(Figure 6D). After deproteinization and purification, addition of
ZGRF1 to the D-loop led to the efficient dissociation of theF1 tagged with YFP were used as a negative control as well as other negative
smic PLA foci for 71–85 cells for each condition. p values were calculated using
.
k denotes 50-32P radiolabel.
alysis of strand exchange catalyzed by RAD51 and RAD54, in the absence or
o protein. The D-loop product was quantified, and data are means ± SD (n = 3).
1/ cells were treatedwith 1 mg/mLMMC for 1 h and allowed to recover in fresh
RAD51. NR 40 cells for each data point.
.
Cell Reports 32, 107849, July 7, 2020 9
ZGRF1        -     4     4     4     4     -     -      -     -     4   (nM)
ZGRF1-K1660A        -      -     -      -      -     4    4     4     4     -   (nM)
Time        12   2     4     8   12    2    4     8    12   12  (min)
ATP       +     +    +     +     +     +    +    +     +      -
*
* dsDNA
MHJ
1    2     3     4     5    6     7     8    9    10
A
N
o 
pr
ot
ei
n
H
D W
T
K1
66
0A
W
T(
-A
TP
)
*
*
5’ D-loop
ssDNA
1   2    3   4   5   6   7 
N
o 
pr
ot
ei
n
H
D W
T
K1
66
0A
W
T(
-A
TP
)
*
*
3’
D-loop
ssDNA
B
C D
1   2    3   4   5   6   7 
D1
D2
D5’
D5’
D1
D2
D3’
D3’
ZGRF1       2.5  5   10  20   -     -    -     -     -    -     -     -     -  (nM)
ZGRF1-K1660A          -    -     -     -   20   -    -     -     -    -     -     -     -  (nM)
FANCM          -    -     -     -    -   2.5  5   10  20   -     -     -     -  (nM)
BLM          -    -     -     -    -     -    -     -     -  2.5   5   10  20 (nM)
D-loop
90-mer
1   2    3    4    5    6    7    8    9   10  11  12  13 14
NP
0
10
20
30
40
50
1 2
ZGRF1 FANCM BLM
3 4 5 6 7 8 9 1011121314
D
-lo
op
 u
nw
ou
nd
 (%
)
lanes
+
+
D1
pBSC D-loop
E
NP   5  10  20 30 20 10 20 40  20 20 nM 
ZGRF1 FANCM
ZG
R
F1
-K
16
60
A
FANCM
ZGRF1
1   2   3   4   5    6   7   8   9  10 11 
90-mer
D-loop+
+
D1
pBSC D-loop
10 20 nM
Figure 6. ZGRF1 Has Branch Migration and D-Loop Dissociation Activity
(A) ZGRF1 has branch migration activity. ZGRF1 or ZGRF1-K1660A was incubated with the movable Holliday junction (MHJ) at 37C for the indicated times with
or without ATP being present.
(B and C) D-loop dissociation by ZGRF1. ZGRF1 (WT) or ZGRF1-K1660A (K1660A) was incubated with D-loop structures with a 50 (B) or 30 (C) ssDNA overhang at
37C for 10 min.
(D) Comparison of extended D-loop dissociation activity of ZGRF1, BLM, and FANCM. The deproteinized Rad51-made D-loops (~2.2 nM) were incubated with
ZGRF1 (2.5–20 nM), ZGRF1-K1660A (20 nM), FANCM (2.5–20 nM), or BLM (2.5–20 nM) at 37C for 10 min. The reaction products were resolved in 0.9% agarose
gels. NP, no protein. The percentage of D-loop unwound was quantified, and data are means ± SD (n = 3).
(E) ZGRF1 and FANCM independently catalyze dissociation of extended Rad51 made D-loops. Rad51-made D-loops were first deproteinized with SDS and
Proteinase K and partially purified. ZGRF1, ZGRF1-K1660A and/or FANCM was incubated with the D-loops at 37C for 10 min. NP, no protein.
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OPEN ACCESSlabeled invading DNA strand (Figure 6D). Side-by-side compar-
ison of this activity with BLM and FANCM indicated that relative
efficiency of D-loop dissociation was greatest with BLM, and
that ZGRF1 and FANCM were similar (Figure 6D). As ZGRF1
andFANCMhave the potential to interact physically (Figure S5B),
we tested if the two proteins would synergize in D-loop dissoci-
ation, but no obvious functional interaction was observed
(Figure 6E). Further comparison of the joint D-loop dissociation
efficiency of FANCM and ZGRF1 showed that a combination of
both enzymes neither stimulated nor inhibited the reaction effi-
ciency (Figure S6A), indicating that FANCM and ZGRF1 can
dissociate D-loops independently of each other in vitro. Finally,
to test if ZGRF1 can dissociate DNA flap structures, we incu-10 Cell Reports 32, 107849, July 7, 2020bated a half D-loop structure with ZGRF1. This substrate was
dissociated by ZGRF1 in amanner dependent on ATP hydrolysis
(Figures S6B) and more efficiently than FANCM (Figures S6C),
indicating that ZGRF1 could play a role in processing these types
of intermediates during DNA repair.
Taken together, the biochemical activities of ZGRF1 are
consistent with an in vivo role of ZGRF1 in promoting HR at repli-
cation-blocking lesions.
DISCUSSION
On the basis of our biochemical, genetic, and cellular analyses,
we propose that ZGRF1 may contribute to several aspects of
Article
ll
OPEN ACCESSrecombinational DNA repair. First, our finding that ZGRF1
physically interacts with RAD51 and stimulates RAD51-RAD54-
catalyzed strand exchange indicates that ZGRF1 could play a
pre-synaptic role in repair of ICLs and other replication-blocking
lesions such as CPT-induced TOP1-DNA covalent intermedi-
ates. Second, ZGRF1may also play a post-synaptic role through
its ability to catalyze D-loop dissociation and HJ branch migra-
tion. Notably, ZGRF1 can dissociate D-loops even without a
free single-stranded tail (Figures 6D and 6E), indicating that
ZGRF1 can use the displaced strand of the D-loop as an entry
point to remodel the D-loop. Using the 50-to-30 directionality of
the ZGRF1 helicase, it may catalyze the partial dissociation of
the 30 end of the extended strand from the D-loop, allowing it
to re-anneal to the other side of the DSB, which could stimulate
the formation of CO products that we observe in the SCE assay
(Figures 4C–4E). The epistatic relationship between FANCM and
ZGRF1 for resistance to MMC (Figure 2F) suggests that the two
proteins act in an interdependent manner to perform the same
function in ICL repair. This would be consistent with the
observed physical interaction between the two proteins (Fig-
ure S5B). Although FANCM and ZGRF1 appear to dissociate
D-loops independently in vitro (Figure 6E), it is possible that
they may work together in this capacity in vivo. The apparent
synthetic lethality between FANCJ and ZGRF1 (Figure 2G) sug-
gests that the two proteins provide a redundant function to ICL
repair. This redundant function is unlikely to be related to the
checkpoint function of FANCJ (Yu et al., 2003), because
ZGRF1 appears to have a functional G2-M checkpoint (Fig-
ure 1E). Instead, it may be the 50-to-30 helicase activity that is
essential and provided by either FANCJ or ZGRF1. In summary,
we favor a model in which ZGRF1 promotes ICL repair by facili-
tating HR through stimulation of RAD51-catalyzed strand ex-
change and possibly also by dissociation of D-loops and HJ
branch migration. A similar contribution to repair may be oper-
ating, when replication forks converge on a CPT-trapped
TOP1-DNA cleavage complex or replication forks collapse at
the DNA nick stabilized by TOP1 trapping.
The lack of sensitivity of ZGRF1/ cells to PARP inhibition is
reminiscent of that reported for some FA patient cell lines (FA-A,
FA-L, FA-D2, FA-I, FA-J), and contrasts with sensitivity of FA-D1
(BRCA2) and FA-P cells (Kim et al., 2013). Interestingly, ZGRF1
depletion and mutation of BRCA1 were reported to cause a syn-
thetic sensitization to PARP inhibitors (Zimmermann et al., 2018),
suggesting that ZGRF1 could be inhibited to eliminate BRCA-
deficient cancer cells. Perhaps in the absence of BRCA1 or
BRCA2 to catalyze recombinational bypass of the trapped
PARP, cells become reliant on ZGRF1 to promote template
switching. The lack of sensitivity of ZGRF1/ cells to HU is
similar to that reported for other ICL repair factors such as
FANCJ, FANCA, BRCA1, and BRCA2 (Chen et al., 2016; Peng
et al., 2018; Schlacher et al., 2011, 2012; Xu et al., 2017). In
contrast, FANCD2 and RAD51 are required for survival after
HU treatment (Chen et al., 2016). A more detailed understanding
of the coordination of ZGRF1 repair activities with that of other
repair factors awaits further epistasis analysis as well as dissec-
tion of its interaction with other proteins.
ZGRF1 forms nuclear foci in response to MMC that mostly
(78%–82%; Figure 3D) colocalize with FANCD2, indicating thatZGRF1 recognizes DNA lesions repaired by the FA pathway.
However, the number of ZGRF1 foci at any given time is low (typi-
cally 2–5 foci; Figure 3) compared with the number of co-local-
izing g-H2AX and FANCD2 foci (typically 9–11 foci; Figure 2D)
observed after the same dose of MMC. The lack of ZGRF1 at
some FANCD2 foci could have several explanations. First,
ZGRF1 may only recognize a subset of the DNA lesions that
are recognized by FANCD2. Second, some ZGRF1 foci may
fall below our detection limit, because ZGRF1 foci are generally
fainter than FANCD2 foci. Third, ZGRF1 may only be recruited to
FANCD2 foci during the recombination step of ICL repair.
Relating to the latter point, it should be noted that some
ZGRF1 foci appear to localize at the periphery of the nucleolus,
which may be related to a previous report that recombinational
repair at the rDNA takes place only after relocalization of the
DNA lesion to the periphery of the nucleolus (van Sluis and
McStay, 2015). It will therefore be important in future studies to
dissect the spatiotemporal relationship between ZGRF1 foci
and other repair factors.
To date, there are no reports of mutations in ZGRF1 associ-
ated with cancer or FA. However, genome-wide association
studies have linked rare missense mutations in ZGRF1 to child-
hood apraxia of speech and obesity (Gao et al., 2015; Peter et al.,
2016). It is worth noting that several other neurological disorders
are caused by mutation in DNA repair genes such as ataxia-tel-
angiectasia (ATM) (Savitsky et al., 1995), oculomotor apraxia
(APTX) (Ahel et al., 2006), spinocerebellar ataxia with axonal neu-
ropathy (TDP1) (Takashima et al., 2002), and motor neuron dis-
ease (SETX) (Hirano et al., 2011), but the role of ZGRF1 in human
pathology awaits future studies.STAR+METHODS
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S4C, S4E, S4F, S5A–S5C, S5E, and S6A–S6C are available through Mendeley (https://data.mendeley.com/datasets/d532xvdrn2/
draft?a=cdd41557-9d54-48fc-bc37-1e63b2be48bb).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines
Human cell lines U2OS (female), HCT116 (male) and hTERT RPE-1 (female) were a gift from Jakob Nilsson (University of Copenha-
gen). Source and identifier (if applicable) of cell lines used in this study are also listed in the key resources table.
Cell culture
Cell lines used in this study are listed in Table S1. Human colorectal carcinoma HCT116 cells were cultured at 37C, 5% CO2 in Mc-
Coy’s 5A (Modified) medium (Life Technologies, cat. no. 26600023), containing 10% heat-inactivated FBS (GIBCO by Life Technol-
ogies, cat. no. 10500-064), and 10,000 units/mL of penicillin and 10,000 mg/mL of streptomycin (GIBCO by Life Technologies, cat. no.
15140-122). Conditioned medium was made by culturing 80% confluent HCT116 cells for 24 h in the above-mentioned medium,
aspirating the medium and centrifuging it at high speed to remove any cells from the suspension.
Human osteosarcoma U2OS and hTERT-immortalized retinal pigment epithelial (hTERT RPE-1) cells were cultured at 37C, 5%
CO2 in complete medium containing DMEM, high glucose, GlutaMAX Supplement, and pyruvate (ThermoFisher Scientific, cat.
no. 31966-021), 10% heat-inactivated FBS (GIBCO by Life Technologies, cat. no. 10500-064), and 10,000 units/mL of penicillin
and 10,000 mg/mL of streptomycin (GIBCO by Life Technologies, cat. no. 15140-122). Conditioned medium was made by culturing
20% confluent U2OS cells for 48 h (so the cells would be 80% confluent after 48 h) in the above-mentioned medium, aspirating the
medium and centrifuging it at high speed to remove any cells from the suspension. The conditionedmediumwas then diluted in com-
plete medium (3:2).
METHOD DETAILS
Design of gRNA
To generate a knockout of ZGRF1, a guide RNA (gRNA) was designed to target the second exon of ZGRF1 (Figure S1A) and have the
fewest off-target hits. Target sequence (including the PAM sequence): AAGTCAAAAGTGTGGCAAGATGG. The designed gRNA was
tested for Cas9 cleavage efficiency of HCT116 genomic DNA in vitro using a Guide-it sgRNA Screening Kit (Takara Bio, cat. no.
632639) according to the manufacturer’s instructions. Single-cell sorted clones were screened for insertions and deletions (indels)
by sequencing and TIDE (Tracking of Indels by Decomposition) analysis (Brinkman et al., 2014). Multiple rounds of sequential trans-
fection yielded several independent ZGRF1/ clones (Figures S1B–S1D). To tag ZGRF1 with 2xYFP, two guides were designed:
Guide A 2xYFP targeting CACTTGTTATTGAAGTATACAGG and Guide B 2xYFP targeting TGTCTCCAGAACTCATCTGTTGG
(PAM sequences underlined). ZGRF1 was knocked out in the U2OS and RPE-1 cell lines essentially as described for the HCT116
cell line. The guides designed to knock out FANCM (Figure S2) and FANCJ (Figure S3) were CGGGACAAGCTCCTCTAGAAAGG
and TGTTTGTTGGAGAGTCCCACAGG (PAM sequences underlined), respectively.
CRISPR/Cas9 plasmids and cloning
Plasmids used in this study are listed in Table S2. Designed gRNAs were cloned into the CRISPR-Cas9 plasmid pX458 (Addgene
plasmid #48138) (Ran et al., 2013) for knocking out ZGRF1, FANCM and FANCJ or into pX461 (Addgene plasmid #48140) for tagging
ZGRF1 with 2xYFP. Briefly, pX458 or pX461 was digested with BbsI, dephosphorylated and gel purified. Two 50-phosphorylated ol-
igonucleotides designed to contain the Cas9 targeting sequence (excluding the PAM sequence), and complementary overhangs to
BbsI digested pX458 or pX461when annealed together, were synthesized (TAGCopenhagen). A guanine (G) was added to the 50 end
of the gRNA as the U6 RNA polymerase III promoter used to express the gRNA prefers this nucleotide as the first base of its transcript
(Ran et al., 2013). Guide primers were mixed in equimolar ratio and annealed using a PCR machine by heating at 95C for 5 min and
ramping down to 25C at a rate of 5C/min. Annealed primers were ligated into BbsI-digested, dephosphorylated pX458 or pX461
and transformed into DH5a E. coli. DNA from ampicillin-resistant clones was screened by restriction digest and sequenced at the
gRNA locus to verify sequence integrity. Guide primers ZGRF1_KO_guide1_FW and ZGRF1_KO_guide1_RV for ZGRF1 knockout
were ligated into pX458 to generate plasmid pAB_KO1. Guide primers ZGRF1_rev_gRNA_FW and ZGRF1_rev_gRNA_RV for
ZGRF1/ reversion were ligated into pX458 to generate plasmid pAB_KO_rev. Guide primers ZGRF1_rev_gRNA3_FW and
ZGRF1_rev_gRNA3_RV for ZGRF1rev/-* reversion were ligated into pX458 to generate plasmid pAB_KO_rev3. GuideA_ZGRF1_FW
and GuideA_ZGRF1_RV were ligated into pX461 to generate plasmid pAB_2xYFP_A for 2xYFP tagging. GuideB_ZGRF1_FW and
GuideB_ZGRF1_RV were ligated into pX461 to generate plasmid pAB_2xYFP_B for 2xYFP tagging. Guide primers FANCJ_KO_gui-
de1_FW and FANCJ_KO_guide1_RV for FANCJ knockout and guide primers FANCM_KO_guide1_FW and FANCM_KO_guide1_RV
for FANCM knockout were ligated into pX458 to generate plasmid pKSV1 and pKSV2, respectively. Oligonucleotides used in this
study are listed in Table S3.Cell Reports 32, 107849, July 7, 2020 e3
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A 1052 bp 50 homology arm placed right before the stop codon of ZGRF1 was amplified by PCR using the primers 50arm_FW and
50arm_RV adding a 50 KpnI and a 30 SalI restriction site. A 872 bp 30 homology arm placed downstream of the ZGRF1 stop codon
was amplified by PCR using the primers 30arm_FW and 30arm_RV adding a 50 BamHI and a 30 NotI restriction site. A 728 bp fragment
encoding Venus YFP (excluding stop codon) with a 50 SalI and 30 EcoRI restriction site and a 720 bp fragment encoding EYFPwith a 50
EcoRI and a 30 BamHI restriction site were synthesized by GeneArt Services at Thermo Fisher Scientific. The four fragments were
cloned into pBluescript SK+ starting with insertion of the homology arms followed by a three-point ligation of the backbone and
the two YFP’s. Subsequently, the BamHI restriction site was used to introduce a loxP-flanked blasticidin S resistance (BSR) cassette
(Arakawa et al., 2001) downstream of the EYFP to create the final plasmid pAK_ZGRF1-2xYFP for tagging ZGRF1 C-terminally with
Venus and EYFP (2xYFP).
Transfection of HCT116 cells
Unless otherwise stated, HCT116 cells were transfected using FuGENE 6 Transfection Reagent (Promega, cat. no. E2311) according
to themanufacturer’s instructions scaled for cell culture plates with Ø = 10 cmand using a FuGENE 6 Transfection Reagent:DNA ratio
of 3:1. For tagging of ZGRF1with 2xYFP, cells were co-transfected with equal moles of pAB_2xYFP_A, pAB_2xYFP_B and linearized
pAK_ZGRF1-2xYFP. To remove the blasticidin resistance cassette, ZGRF1 2xYFP tagged cells were transfected with pCre-GFP and
single cell FACS sorted. It was verified that cells became sensitive to blastidicin (5 mg/mL).
For reverting ZGRF1/ or ZGRF1rev/-* cells, cells were co-transfected with 3.125 mg pAB_KO_rev and 1.875 mg ZGRF1_rev_ssD-
NA_template_2 or 3.125 mg pAB_KO_rev3 and 1.875 mg ZGRF1_rev_ssDNA_template_2, respectively, using Lipofectamine 3000Re-
agent (Invitrogen, cat. no. L3000-015) according to the manufacturer’s instruction scaled for 6-well plate wells. The reverted ZGRF1
allele contained a diagnostic BamHI restriction site for screening candidate clones.
To generate FANCJ mutant and FANCM/ clones, Lipofectamine 3000 Reagent (Invitrogen, cat. no. L3000-015) was used ac-
cording to the manufacturer’s instruction scaled for a 6-well plate. Parental and ZGRF1/HCT116 cells were transfected with either
pKSV1 (FANCJ-KO-gRNA) or pKSV2 (FANCM-KO-gRNA).
mCherry-FANCD2-PuroR expressing cells were obtained by random integration using FuGENE 6 transfection reagent according
to themanufacturer’s instructions scaled for a 6-well plate. HCT116 ZGRF12xYFP/WT cells were transfected with plasmid pKSV15 with
a Reagent:DNA ratio of 3:1. 24 h after transfection, cells were treated with 0.8 mg/mL puromycin dihydrochloride (Thermo Fisher Sci-
entific, cat. no. A1113803) for 3 days in order to select for puromycin resistant cells.
Transfection of U2OS and hTERT RPE-1 cells
U2OS and hTERT RPE-1 cells were transfected using FuGENE 6 Transfection Reagent according to the manufacturer’s instructions
scaled for cell culture plates with Ø = 10 cm and using a FuGENE 6 Transfection Reagent:DNA ratio of 3:1.
Fluorescence activated cell sorting
48 h after transfection, GFP-positive cells were sorted using a BD FACSJazz Cell Sorter (BDBiosciences, cat. no. 655490). Cells were
trypsinized, suspended in growth medium, and then filtered (50 mm; BD Biosciences, cat no. 340629) before sorting. For ZGRF1,
FANCM and FANCJ knockout, single cells were sorted into 96-well plates containing 40% conditioned media and 60% fresh media.
For the ZGRF1 2xYFP tagging, 100 cells were sorted into each well. 5 days later, selection of ZGRF1 2xYFP colonies was performed
using 5 mg/mL blasticidin (GIBCO by Life Technologies, cat. no. A11139-03).
Genotyping of FACS-sorted clones
10 days after cell sorting, genomic DNA was extracted from single colonies. Briefly, cells were gently washed with PBS and 30 mL
QuickExtract DNA Extraction Solution (Lucigen, cat. no. QE09050) was added to each well. The plate was incubated at 70C for
30 min, and 1 mL of each well was used for subsequent PCRs.
A 346 bp region containing the ZGRF1 Cas9 target site was amplified using primers ZGRF1_KO_IDAA_FW and ZGRF1_KO_I-
DAA_RV. The resulting product was gel purified and Sanger sequenced (Eurofins Genomics). Sequences were analyzed for indels
using the online tool TIDE (Tracking of Indels by Decomposition) (Brinkman et al., 2014).
Clones containing indels were validated by fragment length analysis by capillary electrophoresis of FAM-labeled PCR products
spanning the Cas9 targeting site. PCR products were created using a tri-primer PCR strategy as described previously (Yang
et al., 2015). Primer molar ratio used for ZGRF1_KO_IDAA_FAMFW:FamF:ZGRF1_KO_IDAA_RV was 1:10:10.
Analysis of fragment length was carried out by Eurofins Genomics using size standard ROX500 and filter set ABI-D. For each anal-
ysis, a parental HCT116 sample was included for reference.
The strategy to verify FANCJ and FANCM knockout was similar to the description above. A 776 bp region containing the FANCJ
Cas9 target site was amplified using the primers, FANCJ_KO_700_FW and FANCJ_KO_700_RV and a 714 bp region containing the
FANCM Cas9 target site was amplified using the primers FANCM_KO_700_FW and FANCM_KO_700_RV. The resulting PCR prod-
ucts were sequenced and analyzed for indels using the online tool TIDE.
To verify integration of 2xYFP downstream of ZGRF1, a 1180 bp PCR fragment was generated using the primers ZGRF1_outsi-
te_FW2 (binds genomic DNA upstream the ZGRF1 50 homology arm) and ZGRF1_YFP_RV (binds in YFP).e4 Cell Reports 32, 107849, July 7, 2020
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To raise a rabbit antibody against a 102 amino acid N-terminal fragment of ZGRF1, a 306 bp region encoding the ZGRF1 DUF2439
domain was amplified from cDNA by PCR using primers ZGRF1-N-F and ZGRF1-N-R, adding a 50 BamHI and a 30 XmaI restriction
site, and cloned into pGEX-3X (GE Healthcare, cat. no. 28954654) to generate pGEX-3X-ZGRF1-N.
For expression and purification of GST tagged ZGRF1 DUF2439 and untagged ZGRF1 DUF2439, pGEX-3X-ZGRF1-N was trans-
formed into E. coli BL21(DE3). The bacteria were then grown at 37C to OD600 = 0.7 followed by 4 h of expression induction with
100 mM IPTG (Sigma, cat. no. I5502). The culture was harvested at 4000 x g for 10 min followed by washing and re-suspension in
ice-cold RecBuffer (50 mM Piperazine-HCl (Sigma, cat. no. P45907) pH 9.8, 500 mM NaCl, 1 mM DTT (VWR, cat. no. 82021-254),
1 mM EDTA, 0.5 mM PMSF (Roche, cat. no. 10837091001), complete protease inhibitor cocktail (Roche, cat. no. 25735720)).
0.4 mg/mL lysozyme (Sigma, cat. no. L7651) was added and the cells were sonicated for 3 3 30 s in a sonicator (Hielscher,
UP200S, point tip max). To complete cell lysis, the solution was supplemented with 1% Triton X-100 (Sigma, cat. no. T8787) and
rocked 30 min at 4C before it was spun at 16,000 x g for 10 min. Whole cell extract was then incubated with Glutathione Sepharose
4B (GE Healthcare, cat. no. 17-0756-01) while rocking at 4C for 30 min and the protein bound resin was washed with cold RecBuffer
supplemented by 0.1% Triton X-100. To purify GST tagged protein, resin was transferred to a Mobicol ‘‘classic’’ column (MoBiTec,
cat. noM1002) with a 10 mmpore size filter attached (MoBiTec, cat. no. M2210) and the protein was eluted with Elution Buffer (50mM
Tris-HCl pH 8.0, 10mM reduced glutathione (AppliChem, cat. no. A2084), 150mMNaCl, 1mMDTT, 1mMEDTA). To purify untagged
ZGRF1 DUF2439, the protein bound resin was equilibrated with Cleavage Buffer (PBS, 150 mMNaCl, 1 mMCaCl2, pH 7.5) and incu-
bated with Factor Xa protease (Merck, cat. no. 69037) for 24 h at 25C. The concentration of NaCl was then increased to approx.
700 mM to release untagged ZGRF1 DUF2439 from the resin before the GST-bound resin was removed using centrifugal columns
(Merck, cat. no. UFC40SV25). Finally, Factor Xa was removed using the Factor Xa Cleavage Capture Kit (Merck, cat. no. 69037) ac-
cording to the manufacturer’s instructions.
Polyclonal antibodies against the ZGRF1 DUF2439 domain were raised in rabbits by BioGenes GmbH. GST tagged ZGRF1
DUF2439 was used for immunization and untagged ZGRF1 DUF2439 was used for subsequent purification of the serum to remove
antibodies not specific for the DUF2439 domain.
Western blotting
For all western blots in this study, cells were grown to 80% confluency. For visualization of secondary antibodies, ECL mixture (GE
Healthcare, cat. no. RPN2232) was prepared and added to the membrane followed by imaging of chemiluminescence (ImageQuant
LAS 4000).
For western blotting of ZGRF1: Cells were washed once with PBS, and cells isolated using cell scrapers. Cells were centrifuged at
250 x g for 5min at 4C, supernatant was removed, and cells were re-suspended in 800 mL ice-cold PBS. This was followed by centri-
fugation at 2500 x g for 30 s at 4Cand re-suspension in 1.8mLNP-40 buffer (150mMNaCl, 1%NP-40, 50mMTris-HCl pH 8.0, 1mM
PMSF, complete protease inhibitor cocktail). Samples were lysed by syringing through a 23G needle 10 times on ice and centrifuged
at 13000 x g for 20 min at 4C. The supernatant was used for pulldown of ZGRF1 using Dynabeads Protein G (Life Technologies, cat.
no. 10004D) according to the manufacturer’s instructions. To each sample of beads, 2.42 mg anti-ZGRF1 rabbit antibody (BioGenes
GmbH, lot no. 28429) and 1 mg rat anti-tubulin antibody (Abcam, cat. no ab6160) were bound. PBSwith 0.1% Tween-20 was used as
washing buffer. Samples were eluted in 1X SDS sample buffer (2X SDS sample buffer (125 mM Tris-HCl pH 6.8, 5% SDS, 0.004%
Bromophenol Blue, 10% beta-mercaptoethanol, 20% glycerol) diluted 1:2 in RIPA buffer (150 mM NaCl, 1% NP-40, 0.5% sodium
deoxycholate, 0.1% SDS, 50 mM Tris-HCl pH 8.0, 1 mM PMSF, complete protease inhibitor cocktail)) at 70C with shaking at
1000 RPM for 10min. Eluted samples were boiled, run on an SDS-PAGE gel until the 40 kDamarker ran out of the gel, and transferred
to a 0.45 mm ethanol activated PVDFmembrane at 40 mA for 18 h at 4C in an ice bucket. The membrane was cut at 60 kDa to sepa-
rate tubulin from ZGRF1 and blocked with 5% skim milk in TBST for 1 h at room temperature with gentle shaking followed by 3
washeswith TBST for 10min. Eachmembranewas incubatedwith their respective primary antibodies at 4Covernight (1:1000 rabbit
anti-ZGRF1 (BioGenes GmbH, lot no. 28429) in 5% BSA in TBST or 1:20.000 rat anti-tubulin (Abcam, cat. no ab6160) in 5% milk in
TBST). Membranes were washed 3 times with TBST for 10 min and incubated with respective secondary antibodies (1:1000 swine
anti-rabbit (Dako, cat no. P0217) for ZGRF1 and 1:2000 rabbit anti-rat (Dako, cat. no. P0450) for tubulin) in 5% skim milk in TBST for
1 h followed by another 3 washes for 10 min in TBST.
For western blotting of GFP: After syringing and centrifugation, the supernatant was used for pull-down of GFP usingGFP-TrapM
beads (Chromotek, cat. no. gtm-20) according to the manufacturer’s instructions. PBS was used as washing buffer. Samples were
eluted in 2X SDS sample buffer at 95Cwith shaking at 1000 RPM for 10 min. Eluted samples were boiled, run on an SDS-PAGE gel,
transferred to a 0.45 mmnitrocellulosemembrane and blocked as described in the section above. Themembrane was incubated with
primary antibody in 5% BSA in PBST at 4C overnight (1:1000 mouse anti-GFP (Roche Diagnostics, cat. no. 11814460001)). The
membrane was washed 3 times with TBST for 10 min and incubated with secondary antibody (1:1000 rabbit anti-mouse (Dako,
cat. no. P0161)) in 5% skim milk in TBST for 1 h followed by another 3 washes for 10 min in TBST.
For western blotting of FANCM, FANCJ and FANCD2: The appropriate cell lines were harvested by trypsinization. 10million cells of
each cell line were spun down at 250 x g for 5min at 4C. The pellet was resuspended in 1mL ice cold PBS andwashed by spinning at
1300 x g for 30 s at 4C. This was followed by resuspending in 800 mL ice cold PBS and centrifugation at 1300 x g for 30 s at 4C. The
sampleswere then resuspended in 200 mLRIPA buffer and lysed by syringing through a 23G needle 10 times on ice and centrifuged atCell Reports 32, 107849, July 7, 2020 e5
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added. Samples were boiled for 5 min at 95C and run on a precast 4%–20% SDS-PAGE gel (BIO-RAD, cat. no. #456-1093) until the
15 kDa ladder band had run out of the gel. Proteins were transferred to a 0.45 mmnitrocellulose membrane at 40 mA for 18 h at 4C in
an ice bucket withmagnetic stirring. After transfer, themembranewas blockedwith 5%skimmilk in TBST for 1 h at room temperature
with gentle shaking followed by 3 washes with TBST for 10 min. Themembrane was cut between 70 and 100 kDa to separate Tubulin
from FANCM, FANCJ or FANCD2 and then eachmembrane were incubated with their respective primary antibody in 5% skimmilk in
TBST at room temperature for 1 h or for 18 h at 4C (1:500 Mouse anti-FANCM (Novusbio, NBP2-50418), 1:500 Rabbit anti-FANCJ
(Novusbio, NB100-416), 1:2000 Rabbit anti-FANCD2 (Novusbio, NB100-182SS) or 1:5000 Rat anti-Tubulin). Membranes were
washed 3 times with TBST for 5 min and incubated with respective secondary antibodies (1:1000 swine anti-rabbit for FANCJ
and FANCD21:1000, rabbit anti-mouse for FANCM and 1:2000 rabbit anti-rat for tubulin) in 5% skim milk in TBST for 1 h followed
by another 3 washes for 5 min in TBST.
Cell cycle analysis
Parental HCT116 and knockout cell lines were seeded in 10 mL growth media in cell culture plates with Ø = 10 cm at low confluency
(0.2 3 106 cells). The cells were allowed to adhere for 48 h and then treated with 40 ng/mL MMC (Sigma, cat. no. M7949) for 2 h.
Following treatment, the cells were washed with PBS 3 times and incubated in fresh growth media for additional 24 h. Samples
were harvested by trypsinization, spun down at 250 x g for 5 minutes and resuspended in 1 mL PBS. Immediately before fixation
in 70% ice cold ethanol, the cells were filtered (50 mm; BD Biosciences, cat no. 340629) to obtain a mono-dispersed cell suspension.
The fixed cells were stained with propidium iodide as described in Pozarowski and Darzynkiewicz (2004). The cell cycle distribution
was analyzed with a BD FACSJazz Cell Sorter (BD Biosciences, cat. no. 655490).
Colony formation assays
HCT116 parental and ZGRF1/ cells were plated in duplicate and then treated with the indicated doses of DNA-damaging agents.
For the epistasis analysis with FANCM/ cells and FANCJ mutant cells, all cells were seeded in 40% conditioned media. Cells
treated with CPT (Merck, cat. no. C9911) or MMC were washed with fresh media 24h after drug addition. Talazoparib-treated sam-
ples (SMS-Gruppen Denmark, cat. no. S7048) were grown in the presence of the drug continuously until fixation. UV samples were
treated with a 254 nm UV-C irradiator fitted with G15T8 15W germicidal UV tubes, while IR samples were treated with an X-ray irra-
diator (Faxitron, cat. no. CP-160). Cells were grown for 10–12 days after treatment, fixed with methanol:acetic acid (3:1) and stained
with crystal violet in methanol. The surviving fraction at each drug concentration was calculated by normalizing to the plating effi-
ciency of untreated samples. To measure HU sensitivity, HCT116 parental and ZGRF1/ cells were plated in duplicate and allowed
to adhere overnight followed by treatment with the indicated doses of hydroxyurea (Sigma, cat. no. H8627). The samples were grown
in the presence of the drug continuously until fixation 8 days after HU was added.
U2OS and RPE-1 parental and ZGRF1/ cells were plated in duplicate, treated with the indicated doses of DNA-damaging agent
(MMC) and washed with fresh medium 24 h after drug addition. Cells were grown for 12 and 9 days (U2OS and RPE-1 cells, respec-
tively) after treatment, fixed with methanol:acetic acid (3:1) and stained with crystal violet in methanol. Colonies were manually
counted and the surviving fraction at each drug concentration was calculated by normalizing to the plating efficiency of untreated
samples.
DR-GFP recombination assay
U2OS cells with the integrated DR-GFP assay were co-transfected with an I-SceI expression vector (pCBA-I-SceI) together with a
vector expressingmonomeric red fluorescent protein (pCS2-mRFP) in 1:3 ratio tomark the I-SceI-positive cells (Pierce et al., 2001) or
with pCS2-mRFP alone as a negative control. Cells were harvested two days after transfection and subjected to flow cytometric anal-
ysis to examine recombination induced by double-strand breakage. The mRFP-positive sub-populations of cells were analyzed for
HR efficiency to circumvent possible differences in transfection efficiencies. Fluorescence-activated cell sorting data were analyzed
with FlowJo software to reveal the percentage of GFP-positive cells relative to the number of transfected cells (mRFP positive).
Metaphase spreads and chromosomal aberrations
Cells were grown in normal growth media or in media containing MMC for 24 h before harvest. 4 h before harvest, cells were treated
with KaryoMAX colcemid solution in PBS (GIBCO by Life Technologies, cat. no. 15212-012) at a final concentration of 0.1 mg/mL.
Mitotic shake-off was performed and cells were centrifuged at 500 x g for 3 min, washed once with PBS and once with 75 mM
KCl. Cells were centrifuged at 500 x g for 5 min followed by resuspension in 75 mM KCl, incubated on ice for 10 min and centrifuged
at 1000 x g for 10 min at 4C. Cell pellets were washed with, and finally re-suspended in ice-cold methanol:acetic acid (3:1) and
placed at 20C for a minimum of 30 min. Spreads were performed by releasing a 10 mL drop from a height of 30 cm onto a slide
that had been soaked for a minimum of 3 h in methanol:acetic acid (3:1) in a Coplin jar. After drying, DAPI mounting media (4% n-
propyl gallate, 80% glycerol, 1.5 mg/mL DAPI) was added to the slides and a coverslip was applied.
Metaphase spreads were imaged using a microscope (AxioImager Z1; Carl Zeiss) equipped with a 1003 objective lens (Plan Apo-
chromat, NA 1.4; Carl Zeiss), a cooled CCD camera (Orca-ER; Hamamatsu Photonics), differential interference contrast (DIC), and ane6 Cell Reports 32, 107849, July 7, 2020
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(PerkinElmer) software. Images were taken at room temperature with 10 optical sections separated by 0.3 mm.
A chromosome arm gap was defined as having a minimum length equivalent to that of the width of the chromosome arm.
Sister chromatid exchange assay
Cells were seeded at low density and allowed to grow for 24 h before BrdU (Sigma, cat. no. B5002) addition to a final concentration of
10 mM. CPT andMMCwas added at the indicated concentrations and for the indicated time before mitotic shake-off. 42 h after BrdU
addition (two HCT116 doubling times) metaphase spreads were performed as described above. After spreading, dried slides were
aged at 65C for 1 h and stained with 20 mg/mL Hoechst 33258 (Life Technologies, cat. no. C10639) in dH2O for 30 min. This was
followed by washing 3 times with dH2O and slides being placed with the chromosomes facing upward in a tray with just enough
0.1 M phosphate buffer (pH 6.8) to cover the slides. Slides were exposed to 254 nm UV light for 12.5 min in a 254 nm UV Stratalinker
1800 (Stratagene, cat. no. 400072) fitted with five G8T5 8W germicidal UV tubes, followed by another 3 washes in dH2O. Slides were
then incubated with pre-heated 2X saline-sodium citrate (SSC) buffer in a Coplin jar at 65C for 1 h followed by 3 washes in dH2O.
Slides were stained by immersion in a 1:20 solution of Giemsa stain (1g Giemsa powder dissolved in 66 mL glycerol and 66 mL ab-
solute ethanol) in 0.1 M phosphate buffer pH 6.8 for 4 min. Slides were washed in running dH2O and dried with filter paper. Mounting
medium (DPX Mountant for histology, Sigma, cat. no. 06522) was added and a coverslip affixed.
Image capture and analysis was performed using the same microscope and software as described for metaphase spreads.
Fluorescence microscopy and image analysis
For immunofluorescence microscopy, sterile coverslips were placed into the wells of a 24-well plate and cells were seeded at low
density in media with or without MMC. For cells being treated less than 24 h, media was changed to MMC-containing media at
the indicated time. 24 h after seeding, cells were washed twice with PBS and fixed in 3% paraformaldehyde in PBS (adjusted to
pH 7.4) for 10 min at room temperature. Cells were washed 3 times with ice-cold PBS, permeabilized by incubating 10 min with
0.1% Triton X-100 in PBS, washed 3 times for 5 min in PBS and blocked with 3% BSA (Merck, cat. no. A4503) and 22.52 mg/mL
glycine in PBST (PBS+ 0.1% Tween 20) for 60 min. Cells were washed twice with PBS and incubated with primary antibodies
(1:2000 anti-FANCD2 (Novus Biologicals, cat. no. NB100-182SS) and 1:500 anti-gH2AX (Millipore, cat. no. 05-636)) in 3% BSA in
PBST overnight at 4C. The following day cells were washed 3 times with PBS for 5 min. Cells were incubated with secondary an-
tibodies (1:500 Alexa Fluor 568 goat anti-rabbit IgG (Life Technologies, cat no. A-11011) and 1:500 Alexa Fluor 488 goat anti-mouse
IgG (Life Technologies, cat. no. A-21121)) in 3%BSA in PBST (Merck, cat. no. A4503) for 1 h at room temperature in the dark and then
washed 3 times with PBS for 5 min. Samples were counterstained using DAPI mounting media (4% n-propyl gallate, 80% glycerol,
1.5 mg/mL DAPI).
For live cell imaging of ZGRF1-2xYFP, 104 cells were seeded per well in an 8 well m-Slide (Ibidi) in 200 mL of McCoy’s 5A (Modified)
medium, containing 10% heat-inactivated FBS and 10,000 units/mL of penicillin and 10,000 mg/mL of streptomycin, and cultured at
37C, 5% CO2 for 3 days. Cells were synchronized before S phase by adding 2 mM thymidine (Sigma, T1895-1G) 18 h prior to mi-
croscopy. Four hours before microscopy, 20 ng/mL MMC was added to the culture. Thirty minutes before release into S phase,
0.4 mMHoechst 33258 (Sigma, B2883) was added to the media. Cells were release into S phase in Leibovitz’s L-15 medium without
phenol red (GIBCO, cat. no. 21083027) containing 10% fetal calf serum and 0.4 mM Hoechst 33258.
For live cell imaging of ZGRF1-2xYFP andmCherry-FANCD2 (cl 72, 87, 132 and 140), 104 cells were seeded per well in an 8 well m-
Slide (Ibidi) in 200 mL of growthmedia cultured at 37C, 5%CO2 for 3 days. Cells were synchronized before S phase with 2mM thymi-
dine added 18 h prior tomicroscopy. Four hours beforemicroscopy, 20 ng/mLMMCwas added to the culture. Cells were release into
S-phase in Leibovitz’s L-15 medium without phenol red containing 10% fetal calf serum.
Fluorescence was detected and imaged using a microscope (DeltaVision Elite; Applied Precision) equipped with a 1003 objective
lens with a numerical aperture of 1.35 (U-PLAN S-APO, NA 1.4; Olympus), a cooled EMCCD camera (Evolve 512; Photometrics), and
a solid-state illumination source (Insight; Applied Precision, Inc). Immunofluorescence images were taken at room temperature with
10 optical sections separated by 0.33 mm. Live cell images of ZGRF1-2xYFP and ZGRF1-2xYFP mCherry-FANCD2 were taken at
37C with 8 and 15 optical sections respectively, separated by 0.5 mm
Images were acquired with softWoRx (Applied Precision) software. Processing and quantitative measurements of fluorescence
intensities were performed with Volocity software (PerkinElmer).
RAD51 immunostaining and image analysis
Sterile coverslips were placed into the wells of a 24-well plate and cells were seeded at low density in fresh media. The following day,
MMC was added at a concentration of 1000 ng/mL. After 1 h incubation, cells were washed twice with fresh warm medium and al-
lowed to recover in fresh, warm medium for the indicated amount of time before pre-extraction and fixation.
To pre-extract cytosolic proteins, media was removed, and cells were washed twice with PBS. Cells were then incubated with
0.1% Triton X-100 in 20 mM PIPES pH 6.8, 1 mM MgCl2, 10 mM EGTA in ddH2O for 60 s followed by fixation in 4% formaldehyde
and 0.1% Triton X-100 in 20 mM PIPES pH 6.8, 1 mM MgCl2, 10 mM EGTA in ddH2O for 15 minutes. Following fixation, coverslips
were rinsed 4 times with PBS for 5 minutes and saturated overnight by incubation with 3% BSA, 0.5% Triton X-100 in PBS at 4C.Cell Reports 32, 107849, July 7, 2020 e7
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BSA, 22.52 mg/mL glycine in PBST) for 30 min.
Cells were then washed once in PBST and incubated with 1:1000 anti-RAD51 (Bio Academia, cat. no. 70-001) in 3% BSA in PBST
for 90min at room temperature on a rocking table. This was followed by threewashes in PBST for 5minutes and incubation with 1:500
Alexa Fluor 568 goat anti-rabbit IgG (Life Technologies, cat no. A-11011) in 3% BSA in PBST for 45 min (in the dark) at room tem-
perature on a rocking table. Following a further 3 washes with PBST, samples were counterstained using DAPI mounting media
(4% n-propyl gallate, 80% glycerol, 1.5 mg/mL DAPI) and coverslips were sealed to microscopy slides using clear nail polish. Slides
were kept at 4C overnight and imaged the next day.
Fluorescence was detected and images were acquired as described under ‘Fluorescence microscopy and image analysis’. Im-
ages were taken at room temperature with 10 optical sections separated by 0.6 mm and the same laser intensity and exposure
time was used for all images in the same channel. Processing and quantitative measurements of fluorescence intensities were per-
formedwith Volocity software (PerkinElmer). Foci were quantified using a custommeasurement protocol in Volocity with foci for each
cell being automatically counted if they lay within the nucleus (as defined by DAPI staining), exceeded a minimum spot intensity of
400% and were the brightest spots within a radius of 0.4 mm.
Expression and purification of human ZGRF1
The human ZGRF1 cDNA (C4orf21-pCMV6) was purchased from Origene. The ZGRF1 protein coding sequence was introduced into
the pENTRD-TOPO vector (Invitrogen) and then transferred into the pDEST20 vector to generate GST-(TEV)-ZGRF1-(His)6. A bacmid
was prepared in the E. coli strain DH10Bac (Invitrogen) and used to generate a baculovirus in Sf9 insect cells (Invitrogen). Hi5 insect
cells (Invitrogen) were used for ZGRF1 expression. All the purification steps were conducted at 0-4C. Briefly, a cell pellet (8 g, from
~600 mL culture) was suspended in 100 mL of K buffer (20 mM KH2PO4, pH 7.4, 10% glycerol, 0.5 mM EDTA, 0.01% Igepal, and
1 mM DTT) containing a cocktail of protease inhibitors (aprotinin, chymostatin, leupeptin, and pepstatin A at 5 mg/mL each, and
1 mM phenyl-methylsulfonyl fluoride) and 500 mM KCl. Cells were disrupted by sonication, and the crude lysate was subject to ul-
tracentrifugation (100,000 g for 90min). The clarified lysate was incubated with 2mLGlutathione Sepharose 4B resin (GE Healthcare)
for 1.5 h. After washing the resin three timeswith 50mLKbuffer containing 500mMKCl, ZGRF1was elutedwith K buffer with 500mM
KCl and 15 mM reduced glutathione. The elution was incubated with 0.5 mL Ni-NTA resin (QIAGEN) for 2.5 h. After washing the resin
three times with 50 mL K buffer containing 500 mM KCl, once with 25 mL K buffer containing 500 mM KCl and 15 mM imidazole,
ZGRF1 was eluted with three aliquots of 0.6 mL K buffer containing 500 mM KCl and 200 mM imidazole. The eluate was dialyzed
for 12 h against K buffer containing 500 mM KCl. Purified ZGRF1 was stored at 80C in 5 mL aliquots. The yield of highly purified
protein was ~100 mg. Expression and purification of ZGRF1-K1660 followed the same procedures, and with a similar overall yield of
highly purified protein.
Expression and purification of other proteins
FANCM, FANCM-K117R, BLM, RPA, PCNA, RAD51, RAD54, Mph1, yRad51, yRad54, human and yeast Pold and human Polε were
purified to near homogeneity using previously described or similar procedures (Sigurdsson et al., 2002; Singh et al., 2010; Van Komen
et al., 2002; Wilson et al., 2013; Xue et al., 2013, 2016).
ATPase assay
ZGRF1 or ZGRF1-K1660A (6 nM) was incubated with or without fX174 viral (+) strand, fX174 linear dsDNA, fX174 RF1 (30 mM nu-
cleotides or base pairs) in 10 mL buffer (30 mM Tris-HCl, pH 7.5, 2.5 mMMgCl2, 1 mM DTT, 100 mg/mL BSA, 50 mM KCl) containing
0.15mMATP and 25 nCi [g-32P]-ATP at 37C for 10 or 20min. The reactionwas terminated by adding an equal volume of 0.5MEDTA,
followed by thin layer chromatography and phosphorimaging analysis (Xue et al., 2014).
DNA unwinding assay
DNA substrates with a 45nt 50 or 30 ssDNA overhang and a 15bp duplex region were prepared by annealing the corresponding oli-
gonucleotides (with one of the oligonucleotides being labeled with 32P) listed in Table S3. In the unwinding reaction, ZGRF1 or
ZGRF1-K1660A (2.5, 5.0, 10, 20, 40 nM) was incubated with 10 nM substrate in reaction buffer (35 mM Tris-Cl, pH 7.5, 1 mM
DTT, 3 mM ATP, 2 mM MgCl2, 60 mM KCl, and 100 nM of ‘‘trap’’ DNA (the unlabeled form of the oligonucleotide that harbors the
32P label in the substrate) at 30C for 5 min. Reaction mixtures were deproteinized by treatment with SDS (0.1%) and proteinase
K (0.5 mg/mL) for 10 min at 30C and then resolved in a 15% polyacrylamide gel in TAE buffer (40 mM Tris, 20 mM acetate acid
and 1 mM EDTA) at 4C. Gels were dried onto Whatman DE81 paper (Whatman International Limited) and analyzed in a Personal
Molecular Imager FX PhosphorImager (Bio-Rad).
Human RAD51-mediated D-loop formation assay
The D-loop formation assay (Figures 5H and 5I) mediated by human RAD51 and RAD54 was modified as described (Raynard and
Sung, 2009). Briefly, human RAD51 (216 nM) was first incubated with 32P-labeled ssDNA (90-mer, 750 nM nucleotides) at 37C
for 10 min, in a buffer containing 35 mM Tris-HCl, pH 7.5, 2 mM ATP, 100 mg/mL BSA, 1 mM DTT, 20 mM KCl, 1 mM MgCl2,
1 mM CaCl2, 15 mM phosphocreatine and 30 units/mL of creatine phosphokinase, to assemble the RAD51-ssDNA presynaptice8 Cell Reports 32, 107849, July 7, 2020
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K1660A (40 nM), or buffer control was added to the reaction followed by addition of pBluescript supercoiled DNA (48 mMbase pairs).
The reaction was then carried out at 30C for 5, 10 and 20min, deproteinized and reaction products were resolved on a 0.9%agarose
gel in TBE buffer (45 mM Tris-borate, 1 mM EDTA, pH 8.0) at room temperature. Gels were dried and subject to phosphorimaging
analysis. The experiment examining the effect of ZGRF1 on yeast Rad51-Rad54-mediated D-loop formation was carried out in a
similar way except the reaction time at 30C for the final step was 4, 8, 12 min (Figures S5D and S5E).
Holliday junction branch migration assay
The movable Holliday junction (MHJ) substrate was prepared as described (Xue et al., 2014). The indicated concentration of ZGRF1
or ZGRF1-K1660Awas incubated with theMHJ (5 nM) in reaction buffer (25mMTris–HCl, pH 7.5, 1mMDTT, 100 mg/mL BSA, 50mM
KCl, 1 mM MgCl2, 2 mM ATP, 15 mM phosphocreatine and 30 units/mL of creatine phosphokinase). The reaction was incubated at
37C and terminated at the indicated times by treatment with SDS (0.5% final) and proteinase K (0.5 mg/mL) for 5 min at 37C. Re-
action mixtures were resolved in an 8% polyacrylamide gel in TBE buffer (45 mM Tris-borate, 1 mM EDTA, pH 8.0) at 4C. Gels were
dried and subject to phosphorimaging analysis.
D-loop dissociation assay
D-loop substrates with either a 50 or 30 invading strand were made by hybridizing oligonucleotides listed in Table S3. The top, un-
paired ssDNA region in these substrates bears no homology to the bottom DNA strand that is hybridized to a complementary oligo-
nucleotide. These substrates (5 nM) were incubated with ZGRF1 or ZGRF1-K1660A (10 and 20 nM) in reaction buffer (25 mM Tris-Cl,
pH 7.5, 1 mM DTT, 2 mM ATP, 2 mM MgCl2, 50 mM KCl) at 37
C for 10 min. Reaction mixtures were deproteinized before being
resolved in 7% polyacrylamide gel in TAE buffer at 4C and analyzed, as above.
The Rad51-mediated D-loop reaction (250 mL) was performed with a 32P-labeled 90-mer oligonucleotide as described (Xue et al.,
2016). The reaction was deproteinized with SDS and proteinase K. After an extraction with phenol-chloroform-isoamyl alcohol
(25:24:1), the buffer was exchanged with buffer H (35 mM Tris-HCl pH 7.5, 1 mM DTT, 9.3 mM MgCl2, and 30 mM KCl) using a
Zeba Spin-desalting Column (Thermo Scientific). The deproteinized Rad51-made D-loops (~2.2 nM) were incubated with ZGRF1
(5-30 nM), ZGRF1-K1660A (20 nM), or FANCM (10-40 nM) in reaction buffer (25 mM Tris-Cl, pH 7.5, 1 mM DTT, 2 mM ATP, 2 mM
MgCl2, 50 mM KCl) at 37
C for 10 min. Reaction mixtures were deproteinized before being resolved in 0.9% agarose gels in TBE
buffer at 4C and analyzed, as above.
The 50 DNA flap substrate that resembles a branchmigratable D-loop structure was constructed as described (Schwab et al., 2015)
using the oligonucleotides (XX1, XX2, D50F; Table S3). ZGRF1, ZGRF1-K1660A (2 nM), FANCM or FANCM-K117R (4 nM) was incu-
bated with the substrate (5 nM) in reaction buffer (25 mM Tris-Cl, pH 7.5, 1 mMDTT, 1 mMATP, 2 mMMgCl2, 50 mMKCl) at 30
C for
the indicated time. Reaction mixtures were deproteinized before being resolved in 7% polyacrylamide gels in TAE buffer at 4C and
analyzed, as above.
Proximity ligation assay
Sterile coverslipswere placed into thewells of a 24-well plate and 40.000 cells were seeded per well in freshmedia. The following day,
media was replaced with either fresh media or media containing 10 ng/mLMMC. After 24 h treatment, coverslips were washed twice
with PBS and fixed in 3% paraformaldehyde in PBS (adjusted to pH 7.4) for 15 min at room temperature. Cells were washed twice
with PBS for 3min, permeabilized by the addition of 0.1% Triton X-100 in 20mMglycine for 10min and once again washed twice with
PBS.
Blocking, overnight primary antibody incubation, PLA probe incubation, probe ligation, probe amplification, final wash and slide
mounting were all performed using reagents and protocol as recommended by the manufacturer (Duolink PLA Technology, Merck)
with reagent volumes scaled up for 24-well plates. Primary antibodies used were 1:2000 mouse anti-GFP (Roche Diagnostics, cat.
no. 11814460001) and 1:2000 rabbit anti-RAD51 (Bio Academia, cat. no. 70-001). PLA probes used were Duolink In Situ PLA Probe
Anti-Rabbit PLUS (Sigma-Aldrich, cat. no. DUO92002) and Duolink In Situ PLA Probe Anti-Mouse MINUS (Sigma-Aldrich, cat. no.
DUO92004). Ligation and amplification were performed using the Duolink In Situ Detection Reagents Orange (Sigma-Aldrich, cat.
no. DUO92007).
Fluorescence was detected and images were acquired as described under ‘Fluorescence microscopy and image analysis’. Im-
ages were taken at room temperature with 10 optical sections separated by 0.6 mm and the same laser intensity and exposure
time was used for all images in the same channel. Amplified PLA product was visualized in the TRITC channel. Processing and quan-
titative measurements of fluorescence intensities were performed with Volocity software (PerkinElmer). Only foci that overlapped the
DAPI staining of each nucleus were counted.
Co-affinity precipitation of ZGRF1 interactors
GST-tagged ZGRF1 or GST alone (0.3 mg) was incubated with human or budding yeast RAD51 (0.5 mg, Figure 5E), or human or
budding yeast Pold (0.5 mg, Figure S5A), or human Flag-FANCM (0.25 mg, Figure S5B), or human Polε or PCNA, RPA (0.5 mg
each, Figure S5C) in 30 mL K buffer (20 mM KH2PO4, pH 7.4, 10% glycerol, 0.5 mM EDTA, 0.01% Igepal, and 1 mM DTT) with
80 mM KCl for 30 min at 4C. The reaction mixture was incubated with 10 mL of Glutathione Sepharose 4B resin (GE HealthcareCell Reports 32, 107849, July 7, 2020 e9
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eluted with 20 mL of 2% SDS. Twenty percent of the supernatant (S) and SDS elution (E) fractions, and 2% of the wash (W) fraction
were analyzed by 4%–20% gradient SDS-PAGE, transferred to Nitrocellulose membrane (BioRad). Blots were probed with the
following antibodies: GST-ZGRF1 and GST (NEB, E2624S), human RAD51 (Santa Cruz Biotech, sc-8349), yeast Rad51 (lab raised
antibody), human Myc-Pold3 subunit (Thermo Fisher Scientific, R951-25), yeast Flag-Pold3 subunit (Sigma, A8592), FANCM-Flag
(Sigma, A8592), humanHA-Polε1 subunit (Roche, 12013819001), human PCNA (lab raised antibody), humanRPA70 subunit (Abcam,
ab79398). If needed, the blots were incubated with HRP-conjugated secondary antibodies (Pierce 31450 for rabbit anti-mouse IgG-
HRP; Sigma A6154 for goat anti-rabbit IgG-HRP; Santa Cruz Biotech Sc-2032 for goat anti-rat IgG-HRP) before visualization of
protein signals using the ECL kit (Thermo Scientific Pierce).
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analyses were completed using Prism 8 (GraphPad). The applied statistical tests and number of biological replicates are
indicated in the figure legends. No statistical methods or criteria were used to estimate sample size or to include/exclude samples.
Multiple clones andmultiple cell lines were analyzed to confirm results were not caused by clonal variations. Unless otherwise stated,
all experiments were performed at least twice and representative experiments are shown.e10 Cell Reports 32, 107849, July 7, 2020
